Lexicon Pharmaceuticals (LXRX) Downgraded by BidaskClub

Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Monday.

LXRX has been the subject of a number of other research reports. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. ValuEngine lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Finally, Wedbush reiterated an “outperform” rating and set a $38.00 target price on shares of Lexicon Pharmaceuticals in a report on Thursday, November 30th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $28.50.

Lexicon Pharmaceuticals (NASDAQ LXRX) traded down $0.45 during trading hours on Monday, hitting $9.32. 536,489 shares of the company were exchanged, compared to its average volume of 534,765. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65. The stock has a market cap of $984.08, a PE ratio of -7.34 and a beta of 0.24. Lexicon Pharmaceuticals has a 1 year low of $8.07 and a 1 year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.07. The firm had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm’s quarterly revenue was down 2.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.35) EPS. equities analysts predict that Lexicon Pharmaceuticals will post -1.38 earnings per share for the current year.

In other news, Director Public Equities L.P. Invus acquired 180,727 shares of Lexicon Pharmaceuticals stock in a transaction dated Friday, November 17th. The shares were acquired at an average cost of $10.11 per share, for a total transaction of $1,827,149.97. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Lonnel Coats acquired 10,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average price of $9.91 per share, for a total transaction of $99,100.00. Following the completion of the acquisition, the chief executive officer now directly owns 42,985 shares in the company, valued at approximately $425,981.35. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 914,353 shares of company stock worth $8,916,253. 5.77% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock valued at $32,363,000 after purchasing an additional 326,088 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in shares of Lexicon Pharmaceuticals by 25.5% in the 3rd quarter. Pinnacle Associates Ltd. now owns 897,045 shares of the biopharmaceutical company’s stock valued at $11,025,000 after purchasing an additional 182,215 shares in the last quarter. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $9,420,000. Sector Gamma AS raised its holdings in shares of Lexicon Pharmaceuticals by 18.4% in the 3rd quarter. Sector Gamma AS now owns 737,453 shares of the biopharmaceutical company’s stock valued at $9,063,000 after purchasing an additional 114,798 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Lexicon Pharmaceuticals by 3.3% in the 2nd quarter. Northern Trust Corp now owns 614,533 shares of the biopharmaceutical company’s stock valued at $10,109,000 after purchasing an additional 19,525 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Lexicon Pharmaceuticals (LXRX) Downgraded by BidaskClub” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/05/lexicon-pharmaceuticals-lxrx-downgraded-by-bidaskclub.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply